Myrtelle Announces Presentation of Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the American Society of Gene and Cell Therapy 26th Annual Meeting
Wakefield, Mass., May, 16th, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
May 16, 2023
This article is featured on another website.
Go to article
April 17, 2026
From China, Bridging Biopharmaceutical Innovation in Korea - Chime Biologics Empowers a New Landscape for Korea's Biopharma Industry
April 17, 2026
From China, Bridging Biopharmaceutical Innovation in Korea - Chime Biologics Empowers a New Landscape for Korea's Biopharma Industry
June 23, 2026
HiRO at BIO Asia–Taiwan: Advancing Global Clinical Development Together
Collaborating Across APAC at BIO Asia–Taiwan to Advance High‑Quality Cross‑Border Clinical Research Harvest Integrated Research…
June 23, 2026
HiRO at BIO Asia–Taiwan: Advancing Global Clinical Development Together
Collaborating Across APAC at BIO Asia–Taiwan to Advance High‑Quality Cross‑Border Clinical Research Harvest Integrated Research…